Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 19,23€(+721,79%). Der Median liegt bei 19,23€(+721,79%).
| Kaufen | 7 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Perspective Therapeutics to Present at Upcoming March Investor Conferences
SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.» Mehr auf globenewswire.com
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a business update on Wednesday, March 26, 2025 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.» Mehr auf globenewswire.com
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | Sep. 2024 | |
|---|---|---|
| Umsatz | 0,00 | 100,00% |
| Bruttoeinkommen | 0,00 | 100,00% |
| Nettoeinkommen | −13,58 Mio | 38,81% |
| EBITDA | −12,92 Mio | 39,43% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 154,69 Mio€ |
Anzahl Aktien | 67,59 Mio |
52 Wochen-Hoch/Tief | 17,49€ - 2,12€ |
| Dividenden | Nein |
Beta | 1,26 |
KGV (PE Ratio) | −2,77 |
KGWV (PEG Ratio) | 0,08 |
KBV (PB Ratio) | 0,54 |
KUV (PS Ratio) | 501,39 |
Unternehmensprofil
| Name | Perspective Therapeutics Aktie |
| CEO | Johan M. Spoor |
| Mitarbeiter | 116 |
Assets entdecken
Shareholder von Perspective Therapeutics Aktie investieren auch in folgende Assets
